BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Earnest-Silveira L, Christiansen D, Herrmann S, Ralph SA, Das S, Gowans EJ, Torresi J. Large scale production of a mammalian cell derived quadrivalent hepatitis C virus like particle vaccine. J Virol Methods 2016;236:87-92. [PMID: 27373602 DOI: 10.1016/j.jviromet.2016.06.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Masavuli MG, Wijesundara DK, Torresi J, Gowans EJ, Grubor-Bauk B. Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C. Front Microbiol 2017;8:2413. [PMID: 29259601 DOI: 10.3389/fmicb.2017.02413] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
2 Torresi J. The Rationale for a Preventative HCV Virus-Like Particle (VLP) Vaccine. Front Microbiol 2017;8:2163. [PMID: 29163442 DOI: 10.3389/fmicb.2017.02163] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
3 Larue RJ, Kazemi AS, Latulippe DR. Microscale stirred-cell filtration for high-throughput evaluation of separation performance. Biochemical Engineering Journal 2018;130:34-8. [DOI: 10.1016/j.bej.2017.11.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
4 Christiansen D, Earnest-Silveira L, Chua B, Meuleman P, Boo I, Grubor-Bauk B, Jackson DC, Keck ZY, Foung SKH, Drummer HE, Gowans EJ, Torresi J. Immunological responses following administration of a genotype 1a/1b/2/3a quadrivalent HCV VLP vaccine. Sci Rep. 2018;8:6483. [PMID: 29691437 DOI: 10.1038/s41598-018-24762-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
5 Collett S, Torresi J, Silveira LE, Truong VK, Christiansen D, Tran BM, Vincan E, Ramsland PA, Elbourne A. Investigating virus-host cell interactions: Comparative binding forces between hepatitis C virus-like particles and host cell receptors in 2D and 3D cell culture models. J Colloid Interface Sci 2021;592:371-84. [PMID: 33677197 DOI: 10.1016/j.jcis.2021.02.067] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lim EJ, Torresi J. Prevention of Hepatitis C Virus Infection and Liver Cancer. Recent Results Cancer Res 2021;217:107-40. [PMID: 33200364 DOI: 10.1007/978-3-030-57362-1_6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Schlotthauer F, McGregor J, Drummer HE. To Include or Occlude: Rational Engineering of HCV Vaccines for Humoral Immunity. Viruses 2021;13:805. [PMID: 33946211 DOI: 10.3390/v13050805] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sharfstein ST. Non-protein biologic therapeutics. Curr Opin Biotechnol 2018;53:65-75. [PMID: 29289799 DOI: 10.1016/j.copbio.2017.12.014] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
9 Garduño-gonzález KA, Peña-benavides SA, Araújo RG, Castillo-zacarías C, Melchor-martínez EM, Oyervides-muñoz MA, Sosa-hernández JE, Purton S, Iqbal HM, Parra-saldívar R. Current challenges for modern vaccines and perspectives for novel treatment alternatives. Journal of Drug Delivery Science and Technology 2022;70:103222. [DOI: 10.1016/j.jddst.2022.103222] [Reference Citation Analysis]
10 Christiansen D, Earnest-Silveira L, Grubor-Bauk B, Wijesundara DK, Boo I, Ramsland PA, Vincan E, Drummer HE, Gowans EJ, Torresi J. Pre-clinical evaluation of a quadrivalent HCV VLP vaccine in pigs following microneedle delivery. Sci Rep 2019;9:9251. [PMID: 31239471 DOI: 10.1038/s41598-019-45461-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
11 Christiansen D, Earnest-Silveira L, Chua B, Boo I, Drummer HE, Grubor-Bauk B, Gowans EJ, Jackson DC, Torresi J. Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like Receptor 2 Agonists. Viral Immunol 2018;31:338-43. [PMID: 29489437 DOI: 10.1089/vim.2017.0182] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]